{"preliminary_commentary":{"by_channel":{"youtube":37,"podcast":29,"x_thread":13,"bluesky_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04379596\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["trastuzumab deruxtecan"],["trastuzumab deruxtecan","durvalumab"],["trastuzumab deruxtecan","pembrolizumab"]],"indication":"advanced HER2-expressing gastric cancer","name":"DESTINY-Gastric03","nct_id":"NCT04379596","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=destiny-gastric03-nct04379596. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"DG-03","arms":[{"description":"T-DXd and 5-fluorouracil (5-FU)","label":"Arm 1A","type":"EXPERIMENTAL"},{"description":"T-DXd and capecitabine","label":"Arm 1B","type":"EXPERIMENTAL"},{"description":"T-DXd and durvalumab","label":"Arm 1C","type":"EXPERIMENTAL"},{"description":"T-DXd, capecitabine, and oxaliplatin","label":"Arm 1D(b)","type":"EXPERIMENTAL"},{"description":"T-DXd, 5-FU, and durvalumab","label":"Arm 1E(a)","type":"EXPERIMENTAL"},{"description":"T-DXd, capecitabine, and durvalumab","label":"Arm 1E(b)","type":"EXPERIMENTAL"},{"description":"Trastuzumab, 5-FU or capecitabine, and cisplatin or oxaliplatin","label":"Arm 2A","type":"ACTIVE_COMPARATOR"},{"description":"T-DXd monotherapy","label":"Arm 2B","type":"EXPERIMENTAL"},{"description":"T-DXd, 5-FU or capecitabine","label":"Arm 2C","type":"EXPERIMENTAL"},{"description":"T-DXd, pembrolizumab and 5-FU or capecitabine","label":"Arm 2D","type":"EXPERIMENTAL"},{"description":"T-DXd and pembrolizumab","label":"Arm 2E","type":"EXPERIMENTAL"},{"description":"T-DXd, pembrolizumab and 5-FU or capecitabine","label":"Arm 2F","type":"EXPERIMENTAL"},{"description":"T-DXd, Volrustomig and 5-FU or capecitabine","label":"Arm 3A","type":"EXPERIMENTAL"},{"description":"T-DXd, Volrustomig and 5-FU or capecitabine","label":"Arm 3B","type":"EXPERIMENTAL"},{"description":"T-DXd, Rilvegostomig and 5-FU or capecitabine","label":"Arm 4A","type":"EXPERIMENTAL"},{"description":"T-DXd, Rilvegostomig and 5-FU or capecitabine","label":"Arm 4B","type":"EXPERIMENTAL"},{"description":"T-DXd, Volrustomig and 5-FU or capecitabine","label":"Part 5 Main Cohort","type":"EXPERIMENTAL"},{"description":"T-DXd, Volrustomig and 5-FU or capecitabine","label":"Part 5 Cohort 2","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2027-05-04","type":"ESTIMATED"},"conditions":["Gastric Cancer"],"enrollment":{"count":452,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Fluorouracil (5-FU)","otherNames":[],"type":"DRUG"},{"name":"Capecitabine","otherNames":[],"type":"DRUG"},{"name":"Durvalumab","otherNames":["MEDI4736"],"type":"BIOLOGICAL"},{"name":"Oxaliplatin","otherNames":[],"type":"DRUG"},{"name":"Trastuzumab","otherNames":[],"type":"BIOLOGICAL"},{"name":"Trastuzumab deruxtecan","otherNames":["DS-8201a, Enhertu"],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"BIOLOGICAL"},{"name":"Volrustomig","otherNames":["MEDI5752"],"type":"BIOLOGICAL"},{"name":"Rilvegostomig","otherNames":["AZD2936"],"type":"BIOLOGICAL"}],"last_update":"2026-08-28","lead_sponsor":"AstraZeneca","official_title":"A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2-expressing Gastric Cancer (DESTINY-Gastric-03)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-05-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Part 1: Occurrence of adverse events (AEs) and serious adverse events (SAEs), graded according to NCI CTCAE v5.0","timeFrame":"Safety will be assessed up to the follow-up period, approximately 24 months."},{"measure":"Part 1: Ocurrence of dose-limiting toxicities (DLTs)","timeFrame":"Safety will be assessed up to the follow-up period, approximately 24 months."},{"measure":"Part 1: Changes from baseline in laboratory parameters","timeFrame":"Safety will be assessed up to the follow-up period, approximately 24 months."},{"measure":"Part 1: Changes from baseline in vital signs","timeFrame":"Safety will be assessed up to the follow-up period, approximately 24 months."},{"measure":"Part 1: Changes from baseline in electrocardiogram (ECG) results","timeFrame":"Safety will be assessed up to the follow-up period, approximately 24 months."},{"measure":"Part 2, Part 3, Part 4 and Part 5: Endpoint assessed by Investigator per RECIST v1.1: Confirmed Objective Response Rate (ORR)","timeFrame":"(Endpoint: ORR) Efficacy will be assessed at an average of approximately 12 months"}],"references":[{"citation":"Yu J, Mehta R. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257036. doi: 10.6004/jnccn.2025.7036.","pmid":"40341124","type":"DERIVED"}],"start_date":{"date":"2020-06-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)","url":"https://clinicaltrials.gov/study/NCT04379596"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/destiny-gastric03-nct04379596"}